126 related articles for article (PubMed ID: 11241323)
1. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis.
Hengstler JG; Pilch H; Schmidt M; Dahlenburg H; Sagemüller J; Schiffer I; Oesch F; Knapstein PG; Kaina B; Tanner B
Int J Cancer; 2001 Mar; 95(2):121-7. PubMed ID: 11241323
[TBL] [Abstract][Full Text] [Related]
2. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
3. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
Surowiak P; Materna V; Kaplenko I; Spaczyński M; Dietel M; Lage H; Zabel M
Virchows Arch; 2005 Sep; 447(3):626-33. PubMed ID: 15968547
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
5. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices.
Ioachim EE; Charchanti AV; Stavropoulos NE; Athanassiou ED; Michael MC; Agnantis NJ
Anticancer Res; 2001; 21(3B):1757-61. PubMed ID: 11497256
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
8. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
9. Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer.
Hengstler JG; Tanner B; Möller L; Meinert R; Kaina B
Int J Cancer; 1999 Aug; 84(4):388-95. PubMed ID: 10404091
[TBL] [Abstract][Full Text] [Related]
10. Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer.
Arriaga JM; Bravo IA; Bruno L; Morales Bayo S; Hannois A; Sanchez Loria F; Pairola F; Huertas E; Roberti MP; Rocca YS; Aris M; Barrio MM; Baffa Trasci S; Levy EM; Mordoh J; Bianchini M
Hum Pathol; 2012 Oct; 43(10):1695-703. PubMed ID: 22516242
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
12. Nuclear expression of apurinic/apyrimidinic endonuclease increases with progression of ovarian carcinomas.
Tanner B; Grimme S; Schiffer I; Heimerdinger C; Schmidt M; Dutkowski P; Neubert S; Oesch F; Franzen A; Kölbl H; Fritz G; Kaina B; Hengstler JG
Gynecol Oncol; 2004 Feb; 92(2):568-77. PubMed ID: 14766249
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
15. Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumors.
Tan Y; Sinniah R; Bay BH; Singh G
Int J Gynecol Pathol; 1999 Oct; 18(4):344-50. PubMed ID: 10542943
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
17. Basal and copper-induced expression of metallothionein isoform 1,2 and 3 genes in epithelial cancer cells: The role of tumor suppressor p53.
Ostrakhovitch EA; Song YP; Cherian MG
J Trace Elem Med Biol; 2016 May; 35():18-29. PubMed ID: 27049123
[TBL] [Abstract][Full Text] [Related]
18. Localization of metallothionein in breast carcinomas. An immunohistochemical study.
Fresno M; Wu W; Rodriguez JM; Nadji M
Virchows Arch A Pathol Anat Histopathol; 1993; 423(3):215-9. PubMed ID: 8236816
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.
Andrews PA; Murphy MP; Howell SB
Cancer Chemother Pharmacol; 1987; 19(2):149-54. PubMed ID: 3568272
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
